M&A Deal Summary |
|
|---|---|
| Date | 2013-11-27 |
| Target | Almaviva Sante |
| Sector | Healthcare Services |
| Buyer(s) |
GIMV
UI Gestion SA |
| Sellers(s) | 21 Invest |
| Deal Type | Secondary Buyout |
| Advisor(s) | DC Advisory (Financial) |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1980 |
| PE ASSETS | 2.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.
| DEAL STATS | # |
|---|---|
| Overall | 84 of 170 |
| Sector: Healthcare Services M&A | 3 of 9 |
| Type: Secondary Buyout M&A Deals | 12 of 28 |
| Country: France M&A | 13 of 32 |
| Year: 2013 M&A | 10 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-09-12 |
Covagen AG
Zurich, Switzerland Covagen is a clinical stage company that develops bispecific FynomAbs by fusing its human Fynomer® binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy. Our current pipeline is focussed on the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-01-01 |
Punch Powertrain
Sint-Truiden, Belgium Punch Powertrain offers full in-house development capabilities, advanced testing facilities, and manufacturing assets. Punch Powertrain was founded in 1972 and is based in Sint-Truiden, Belgium. |
Sell | - |
| Category | Private Equity Firm |
|---|---|
| PE ASSETS | 600M EUR |
| Size | Middle-Market |
| Type | Sector Agnostic |
UI Gestion SA is a private equity firm focused on acquiring and investing in small to mid-sized French companies. UI Gestion seeks businesses with up to €50 million in revenue and is a generalist investor with no sector preferences. UI Gestion SA is based in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 84 |
| Sector: Healthcare Services M&A | 1 of 6 |
| Type: Secondary Buyout M&A Deals | 3 of 11 |
| Country: France M&A | 9 of 84 |
| Year: 2013 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-09-01 |
Tournus Equipement
Tournus, France Tournus Equipement designs, manufactures, and sells stainless steel kitchen equipment (fittings, tables, trolleys, cupboards, shelves: “the stainless steel set”) for the catering & the food trade. The company also makes self-service lines equipment and fish counters for supermarkets. Tournus Equipement was founded in 1910 and is based in Tournus, France. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-06-01 |
Lacroix Emballage
Bois-d'Amont, France Lacroix Emballage is a manufacturer of industrial package series, offers packaging made of wood, cardboard and plastic for the agri-food and non-food industries. Lacroix Emballage was founded in 1946 and is based in Bois-d'Amont, France. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1992 |
| PE ASSETS | 1.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
21 Invest is a private equity firm that targets investments in growth-oriented, middle-market Italian, French, and Polish companies operating in a variety of industries. The Firm invests in French businesses through 21 Centrale Partners, Italian companies through 21 Partners SGR, and Polish companies through 21 Concordia. The Firm targets transactions requiring at least €10 million of capital typically in the form of development capital for growth companies, buyout capital for managers, or replacement capital for companies facing succession issues or needing shareholder liquidity. 21 Invest was founded in 1992 and is based in Treviso, Italy.
| DEAL STATS | # |
|---|---|
| Overall | 19 of 45 |
| Sector: Healthcare Services M&A | 1 of 1 |
| Type: Secondary Buyout M&A Deals | 9 of 26 |
| Country: France M&A | 11 of 22 |
| Year: 2013 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-11-19 |
Meribel Pharma Solutions
Entzheim, France Meribel Pharma Solutions is a pharmaceutical contract development and manufacturing organization (CDMO). Meribel Pharma Solutions develops, manufactures, and packages drugs in various forms (solid, liquid…) on value-adding niches, specialized in small and medium-sized batches. Meribel Pharma Solutions was founded in 2001 and is based in Entzheim, France. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-01-01 |
Monevia
Bydgoszcz, Poland Monevia is a provider of liquidity enhancement solutions for SMEs segment in Poland. Monevia purchases non-overdue invoices from small and micro-enterprises. The service is an alternative to factoring, rarely offered by other financial institutions to small and micro enterprises in Poland. Monevia is based in Bydgoszcz, Poland. |
Buy | - |
